Drugs / Metabolically Armed GPC3 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07487402 | Mar 2026 → Dec 2028 expected | hepatocellular carcinoma | Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metabolically Armed GPC3 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487402 ↗ |
| Modality | Cell therapy | “metabolically armed GPC3 CAR-T cells(Meta10-GPC3)” NCT07487402 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT07487402 ↗ |
| Target | GPC3 | “metabolically armed GPC3 CAR-T cells(Meta10-GPC3)” NCT07487402 ↗ |